parallax background

Supervisor Database Search

Search for supervisors below. You can filter your search using the options and select
multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year. You can read the ICAT supervisor policy here.

Full NameProfessor Dan Longley

Department:Patrick Johnston Centre for Cancer Research

Organisation:Queen's University Belfast

Webpage:qub.ac.uk

Email Address:Email hidden; Javascript is required.

Research Fields
  • cancer/oncology
Postgrad Medical Specialties
  • Medicine
Medical Subspecialties
  • Clinical Trials
  • Oncology
My Work

My research is focussed on the extrinsic apoptotic pathway regulated by death receptors. In particular, my work investigates the predictive, prognostic and therapeutic relevance of the caspase 8 inhibitor FLIP and the inhibitor of apoptosis proteins (IAPs). We have shown that FLIP and IAPs are key regulators of death receptor-, chemotherapy- and radiation-induced apoptosis in a range of in vitro and in vivo cancer models. Based on this work (accepted for publication in Mol Cancer Therapeutics), we are currently planning a phase-I clinical trial to examine the combination of a novel IAP inhibitor tolinapant (Astex Pharmaceuticals) with standard-of-care chemotherapy (FOLFOX) in metastatic colorectal cancer.

Potential Projects

The projects will involve exploring novel methods to overcome resistance to standard-of-care chemotherapy in colorectal cancer. Novel mechanisms of resistance relating to cell death and immunity identified from analysis of clinical cohorts will be explored in advanced pre-clinical models of colorectal cancer. There will be a focus on direct (eg. FLIP and IAP inhibitors) and indirect (eg. histone deacetylase inhibitors) modulators of cell death and immunity, which have direct line of sight to clinical trials in biomarker-definable subgroups of patients with drug resistant, poor prognostic disease. The aim is to provide evidence for clinical trials not only in the advanced metastatic disease setting, but also in the neo-adjuvant disease setting.